LOLA (L-ornithine L-aspartate)
What studies of LOLA (L-ornithine L-aspartate) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for cognition (brain fog).
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: LOLA (L-ornithine L-aspartate) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- LOLA (L-ornithine L-aspartate) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Cognition (brain fog)1 study · 30 people took LOLA (L-ornithine L-aspartate) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (30 in all); not all results were tested against chance.
Studies with no comparison group30 in the study
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of LOLA (L-ornithine L-aspartate) on cognition (brain fog) in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (30 in all)
- Not all results were tested against chance
See the 1 study
-
[Mild post-COVID syndrome in young patients]. (2023)
- People in the study
- 30 in the study
- Dose
- —
- Outcome
- testing results for changes in cognitive functions
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- [Mild post-COVID syndrome in young patients].2023 · no comparison group · 30 in the study
Summary
This single-arm study enrolled 30 students aged 18 to 24 who had COVID-19 and reported decreased attention, memory impairment, and other cognitive disorders. The setting was post-COVID syndrome, and the abstract describes patients without pronounced impairment of intelligence, memory, speech, and learning ability. All patients were treated with L-ornithine-L-aspartate; the abstract does not report dose, route, schedule, or treatment duration. There was no comparison group, and the abstract does not report randomisation, blinding, or a follow-up period. The recorded outcomes were objective findings and testing results for changes in cognitive functions. The abstract reports an improvement in objective findings and an improvement in testing results for changes in cognitive functions. The study size recorded is 30 enrolled; the abstract does not give a separate number started or analysed. Harms, side effects, and withdrawals are not reported. The authors' conclusion states that improvement in objective findings and cognitive testing was reported. The abstract does not state limitations.